Protective effect of concurrent bupropion and citicoline treatment on lipopolysaccharide-induced depression- and anxiety-like behavior in mice: The role of neuroinflammation.

IF 2.2 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Experimental and clinical psychopharmacology Pub Date : 2026-04-01 Epub Date: 2026-03-23 DOI:10.1037/pha0000845
Seyyedeh Elaheh Mousavi, Zeinab Afrand Khalilabad, Moein Ghasemi, Ali Lesani, Seyedeh Sahar Alemohammad, Amirabbas Mohammadi Hamaneh
{"title":"Protective effect of concurrent bupropion and citicoline treatment on lipopolysaccharide-induced depression- and anxiety-like behavior in mice: The role of neuroinflammation.","authors":"Seyyedeh Elaheh Mousavi, Zeinab Afrand Khalilabad, Moein Ghasemi, Ali Lesani, Seyedeh Sahar Alemohammad, Amirabbas Mohammadi Hamaneh","doi":"10.1037/pha0000845","DOIUrl":null,"url":null,"abstract":"<p><p>Depression and anxiety cause substantial functional disabilities, and current treatments often have limited efficacy and notable adverse effects. Developing adjunctive therapies may help address these shortcomings. With established neuroprotective and antidepressant properties, citicoline may improve outcomes and minimize adverse effects. To assess citicoline as an adjuvant to bupropion in a lipopolysaccharide-induced model of depression and anxiety. Six-week-old male Naval Medical Research Institute mice were assigned to control or experimental groups receiving lipopolysaccharide alone or followed by daily bupropion (60 or 100 mg/kg), citicoline (25 or 75 mg/kg), or their combination. On Day 14, behavioral evaluations were performed in 8-week-old mice using the elevated plus maze, open field test, and forced swimming test, and hippocampal tumor necrosis factor-alpha, interleukin-1beta, malondialdehyde, and nitric oxide levels were assessed. Coadministration of low-dose bupropion (60 mg/kg) with an otherwise ineffective dose of citicoline (25 mg/kg) significantly improved anxiety- and depression-like behaviors in the elevated plus maze and forced swimming test and reduced hippocampal tumor necrosis factor-alpha, interleukin-1beta, malondialdehyde, and nitric oxide metabolites. These effects were consistently greater than those of bupropion (60 mg/kg) alone and were comparable or even superior to those achieved with the higher bupropion dose (100 mg/kg). Citicoline appears to positively potentiate bupropion's efficacy against depression- and anxiety-like behaviors in preclinical models of these human disorders, at least in part through attenuation of neuroinflammatory and oxidative processes. These findings suggest a promising experimental strategy that may help guide future clinical studies, particularly for unresponsive individuals. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":"196-206"},"PeriodicalIF":2.2000,"publicationDate":"2026-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1037/pha0000845","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Depression and anxiety cause substantial functional disabilities, and current treatments often have limited efficacy and notable adverse effects. Developing adjunctive therapies may help address these shortcomings. With established neuroprotective and antidepressant properties, citicoline may improve outcomes and minimize adverse effects. To assess citicoline as an adjuvant to bupropion in a lipopolysaccharide-induced model of depression and anxiety. Six-week-old male Naval Medical Research Institute mice were assigned to control or experimental groups receiving lipopolysaccharide alone or followed by daily bupropion (60 or 100 mg/kg), citicoline (25 or 75 mg/kg), or their combination. On Day 14, behavioral evaluations were performed in 8-week-old mice using the elevated plus maze, open field test, and forced swimming test, and hippocampal tumor necrosis factor-alpha, interleukin-1beta, malondialdehyde, and nitric oxide levels were assessed. Coadministration of low-dose bupropion (60 mg/kg) with an otherwise ineffective dose of citicoline (25 mg/kg) significantly improved anxiety- and depression-like behaviors in the elevated plus maze and forced swimming test and reduced hippocampal tumor necrosis factor-alpha, interleukin-1beta, malondialdehyde, and nitric oxide metabolites. These effects were consistently greater than those of bupropion (60 mg/kg) alone and were comparable or even superior to those achieved with the higher bupropion dose (100 mg/kg). Citicoline appears to positively potentiate bupropion's efficacy against depression- and anxiety-like behaviors in preclinical models of these human disorders, at least in part through attenuation of neuroinflammatory and oxidative processes. These findings suggest a promising experimental strategy that may help guide future clinical studies, particularly for unresponsive individuals. (PsycInfo Database Record (c) 2026 APA, all rights reserved).

安非他酮和胞胆碱同时治疗对脂多糖诱导小鼠抑郁和焦虑样行为的保护作用:神经炎症的作用。
抑郁和焦虑会导致严重的功能障碍,目前的治疗方法往往疗效有限,副作用明显。开发辅助疗法可能有助于解决这些缺点。由于具有神经保护和抗抑郁的特性,胞胆碱可以改善预后并减少不良反应。在脂多糖诱导的抑郁和焦虑模型中,评价胞胆碱对安非他酮的辅助作用。6周龄雄性海军医学研究所小鼠被分为对照组和实验组,分别单独给予脂多糖或随后每日给予安非他酮(60或100 mg/kg)、胞胆碱(25或75 mg/kg)或两者的组合。第14天,对8周龄小鼠进行行为学评估,采用升高+迷宫、开放场试验和强迫游泳试验,并评估海马肿瘤坏死因子- α、白细胞介素-1 β、丙二醛和一氧化氮水平。低剂量安非他酮(60 mg/kg)与其他无效剂量的胞胆碱(25 mg/kg)联合使用可显著改善升高+迷宫和强迫游泳试验中的焦虑和抑郁样行为,降低海马肿瘤坏死因子- α、白细胞介素-1 β、丙二醛和一氧化氮代谢物。这些效果始终大于单独使用安非他酮(60 mg/kg)的效果,并且与使用高剂量安非他酮(100 mg/kg)的效果相当甚至更好。在这些人类疾病的临床前模型中,胞胆碱似乎积极增强了安非他酮对抗抑郁和焦虑样行为的功效,至少部分是通过抑制神经炎症和氧化过程。这些发现提出了一个有希望的实验策略,可能有助于指导未来的临床研究,特别是对无反应的个体。(PsycInfo数据库记录(c) 2026 APA,版权所有)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.20
自引率
8.70%
发文量
164
审稿时长
6-12 weeks
期刊介绍: Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书